严重高脂血症继发血色病1例报道及相关文献复习
A Case Report of Hemochromatosis Secondary to Severe Hyperlipidemia and Review of Relevant Literature
DOI: 10.12677/acm.2024.1441241, PDF,   
作者: 辛倩玉, 林 华, 崔宇琨, 张 芳, 王颜刚, 吕文山:青岛大学附属医院内分泌与代谢性疾病科,山东 青岛;杨利波:青岛大学附属泰安市中心医院内分泌科,山东 青岛;刘云婷:北京迈基诺空港医学检验室有限责任公司,北京;王雪梅:青岛大学附属医院内科学教研室,山东 青岛;杨丽丽*:青岛大学附属医院门诊部,山东 青岛
关键词: 高脂血症血色病铁代谢紊乱酒精性肝病PCSK9抑制剂Hyperlipidemia Hemochromatosis Iron Metabolism Disorders Alcoholic Liver Diseases PCSK9 Inhibitors
摘要: 目的:报道高脂血症继发血色病1例,总结患者临床资料,探讨该类疾病临床特征及诊疗要点。方法:收集1例反复严重脂代谢紊乱导致肝脏铁沉积的继发性血色病患者临床资料,并对相关文献进行复习。结果:患者老年男性,以纳差、乏力、恶心为主要临床表现。实验室检查示,血脂异常(以甘油三酯极重度升高及重度高胆固醇血症为主)、重度肝功能异常、铁蛋白升高、血糖升高,上腹部MR检查示肝脏铁沉积,给予调脂及护肝治疗后,患者血脂、铁蛋白水平改善不理想。8个月后患者再次出现重度血脂代谢紊乱、肝功能异常及铁蛋白升高,上腹部MRI检查仍显示肝脏铁沉积。基因全外显子测序发现PCSK9基因3号外显子存在c.503C > T (p.Ala168Val)错义变异,加用阿利西尤单抗调脂治疗。7月后复查肝功能、血脂、铁代谢指标恢复正常,铁沉积不显著。结论:严重高脂血症继发血色病,遗传学分析有助于指导临床精准治疗。
Abstract: Objective: This study aims to report a case of hemochromatosis secondary to hyperlipidemia, summarize the patient’s clinical data, and explore the clinical characteristics and key points of diagnosis and treatment of this type of disease. Methods: The clinical data of a patient with secondary hemochromatosis who suffered from repeated severe lipid metabolism disorders leading to hepatic iron deposition were collected, and the relevant literature was reviewed in this paper. Results: The patient was an elderly male with poor appetite, fatigue, and nausea as the main clinical manifestations. Laboratory tests showed abnormal blood lipids (mainly extremely elevated triglycerides and severe hypercholesterolemia), severe liver function abnormalities, elevated ferritin, and elevated blood sugar. MRI examination of the upper abdomen showed iron deposition in the liver. After lipid-lowering and liver-protecting treatment, the patient’s blood lipid and ferritin levels did not improve satisfactorily. Eight months later, the patient again developed severe lipid metabolism disorder, abnormal liver function, and elevated ferritin. Upper abdominal MRI examination still showed iron deposition in the liver. Whole-exome sequencing of the gene revealed that there was a c.503C > T (p.Ala168Val) mis-sense mutation in exon 3 of the PCSK9 gene, and lipid- lowering treatment with alircizumab was added. After 7 months, the liver function, blood lipids, and iron metabolism indicators returned to normal, and iron deposition was not significant. Conclusion: For hemochromatosis secondary to severe hyperlipidemia, genetic analysis can help guide precise clinical treatment.
文章引用:辛倩玉, 杨利波, 刘云婷, 王雪梅, 林华, 崔宇琨, 张芳, 王颜刚, 吕文山, 杨丽丽. 严重高脂血症继发血色病1例报道及相关文献复习[J]. 临床医学进展, 2024, 14(4): 1892-1898. https://doi.org/10.12677/acm.2024.1441241

参考文献

[1] Gattermann, N. (2009) The Treatment of Secondary Hemochromatosis. Deutsches Arzteblatt International, 106, 499-504. [Google Scholar] [CrossRef] [PubMed]
[2] Crawford, D.H.G., Ramm, G.A., Bridle, K.R., et al. (2023) Clinical Practice Guidelines on Hemochromatosis: Asian Pacific Association for the Study of the Liver. Hepatology International, 17, 522-541. [Google Scholar] [CrossRef] [PubMed]
[3] Hsu, C.C., Senussi, N.H., Fertrin, K.Y., et al. (2022) Iron Overload Disorders. Hepatology Communications, 6, 1842-1854. [Google Scholar] [CrossRef] [PubMed]
[4] Pinyopornpanish, K., Tantiworawit, A., Leerapun, A., et al. (2023) Secondary Iron Overload and the Liver: A Comprehensive Review. Journal of Clinical and Translational Hepatology, 11, 932-941.
[5] Malcovati, L., Porta, M.G., Pascutto, C., et al. (2005) Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23, 7594-7603. [Google Scholar] [CrossRef
[6] 王琳. 活血化痰配伍对高脂血症合并铁代谢异常小鼠的保护效应研究[D]: [硕士学位论文]. 兰州: 甘肃中医药大学中西医结合临床, 2016.
[7] Bacon, B.R., Adams, P.C., Kowdley, K.V., et al. (2011) Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.), 54, 328-343. [Google Scholar] [CrossRef] [PubMed]
[8] 中华医学会, 中华医学会杂志社, 中华医学会消化病学分会. 酒精性肝病基层诊疗指南(2019年) [J]. 中华全科医师杂志, 2020, 19(11): 990-996.
[9] 薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227.
[10] Dongiovanni, P., Lanti, C., Gatti, S., et al. (2015) High Fat Diet Subverts Hepatocellular Iron Uptake Determining Dysmetabolic Iron Overload. PLOS ONE, 10, e0116855. [Google Scholar] [CrossRef] [PubMed]
[11] Horton, J.D., Cohen, J.C. and Hobbs, H.H. (2009) PCSK9: A Convertase That Coordinates LDL Catabolism. Journal of Lipid Research, 50, S172-S177. [Google Scholar] [CrossRef
[12] Abifadel, M., Varret, M., Rabès, J.P., et al. (2003) Mutations in PCSK9 Cause Autosomal Dominant Hypercholesterolemia. Nature Genetics, 34, 154-156. [Google Scholar] [CrossRef] [PubMed]
[13] Cunningham, D., Danley, D.E., Geoghegan, K.F., et al. (2007) Structural and Biophysical Studies of PCSK9 and Its Mutants Linked to Familial Hypercholesterolemia. Nature Structural & Molecular Biology, 14, 413-419. [Google Scholar] [CrossRef] [PubMed]
[14] 封思琴, 王一斐, 陈沛沛. PCSK9抑制剂多效性的研究进展[J]. 中华心血管病杂志, 2022, 50(3): 313-318.
[15] Varret, M., Rabès, J.P., Saint-Jore, B., et al. (1999) A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32. American Journal of Human Genetics, 64, 1378-1387. [Google Scholar] [CrossRef] [PubMed]
[16] 中华医学会心血管病学分会动脉粥样硬化及冠心病学组, 中华心血管病杂志编辑委员会. 家族性高胆固醇血症筛查与诊治中国专家共识[J]. 中华心血管病杂志, 2018, 46(2): 99-103.
[17] Hori, M., Ohta, N., Takahashi, A., et al. (2019) Impact of LDLR and PCSK9 Pathogenic Variants in Japanese Heterozygous Familial Hypercholesterolemia Patients. Atherosclerosis, 289, 101-108. [Google Scholar] [CrossRef] [PubMed]
[18] 彭彦人, 陈国军, 郑华. PCSK9抑制剂对不同基线水平的甘油三酯降低效果不同[J]. 南方医科大学学报, 2020, 40(8): 1141-1147.
[19] Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine, 376, 1713-1722. [Google Scholar] [CrossRef
[20] Peng, Y., Guo, D., Jiang, S., et al. (2022) Application of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, Evolocumab, in Patients with Severe Hypertriglyceridemia. Chinese Medical Journal, 135, 730-731. [Google Scholar] [CrossRef
[21] Lohoff, F.W., Sorcher, J.L., Rosen, A.D., et al. (2018) Methylomic Profiling and Replication Implicates Deregulation of PCSK9 in Alcohol Use Disorder. Molecular Psychiatry, 23, 1900-1910. [Google Scholar] [CrossRef] [PubMed]
[22] Lee, J.S., Mukhopadhyay, P., Matyas, C., et al. (2019) PCSK9 Inhibition as a Novel Therapeutic Target for Alcoholic Liver Disease. Scientific Reports, 9, Article No. 17167. [Google Scholar] [CrossRef] [PubMed]